One of the most significant viral infections causing respiratory illnesses is RSV. From cold-like symptoms to life-threatening lower respiratory tract infections, clinical symptoms can range greatly. Additionally, exacerbations of underlying cardiopulmonary illness have been linked to RSV as a cause. Long-term care facility residents, people with underlying lung and/or heart conditions, the elderly, and people with immunocompromised patients (especially those who are actively receiving chemotherapy for hematologic malignancies) are all at a higher risk of developing severe RSV diseas. Many people still underestimate the severity of RSV disease due to insensitive RSV detection techniques and a general lack of RSV screening [1]. In fact, mounting data indicate that RSV is both more common and expensive than previously believed. For instance, a recent metanalysis when a nasopharyngeal RT-PCR test was combined with a sputum RT-PCR test or by using paired serology specimens, RSV detection was found to be 1.4–2 times higher. RSV is anticipated to be the cause of around 159,000 hospitalizations, 119,000 ED admissions, and 1.4 million outpatient visits each year among US people aged 65 and older, according to data from previous assessments applied to the population of the US Census in 2022 [2].